IntraDose-CDDP data

MATX (Menlo Park, Calif.) presented Phase I/II results in 31 patients, showing an overall response rate of 55 percent.

The complete response (CR) rate in 71 evaluable tumors was 334 (48 percent). A typical CR in tumors of this type ranges from 10 to 30 percent, MATX said. ...